Use of flibanserin in the treatment of obesity

Information

  • Patent Grant
  • 8227476
  • Patent Number
    8,227,476
  • Date Filed
    Monday, July 31, 2006
    17 years ago
  • Date Issued
    Tuesday, July 24, 2012
    11 years ago
Abstract
The invention relates to a method for the treatment of obesity and related diseases comprising the administration of a therapeutically effective amount of Flibanserin.
Description
RELATED APPLICATIONS

This application is filed pursuant to 35 U.S.C. 371 and constitutes the national stage of International Application PCT/EP2006/064825 filed Jul. 31, 2006.


The invention relates to a method for the treatment of obesity and related diseases, comprising the administration of a therapeutically effective amount of Flibanserin. The invention relates further to new pharmaceutical compositions for the treatment of obesity and related diseases.


BACKGROUND OF THE INVENTION

The intake of food and its conversion in the body is an essential part of life for all living creatures. Therefore, deviations in the intake and conversion of food generally lead to problems and also illness. The changes in the lifestyle and nutrition of humans, particularly in industrialised countries, have promoted morbid overweight (also known as corpulence or obesity) in recent decades.


The prevalence of obesity has risen significantly in the past decade in the United States and many other developed countries, (Fiegal et al, Int. J. Obesity 22:39-47 (1998), Mokdad et al, JAMA 282:1519-1522 (1999)). Because obesity is associated with a significantly elevated risk for diabetes, especially for type 2 diabetes, dyslipidaemia, arteriosclerosis, coronary heart disease, hypertension, and numerous other major illnesses, and overall mortality from all causes (Must et al, JAMA 282:1523-1529 (1999), Calle et al, N. Engl. J. Med. 341:1097-1105 (1999)), weight reduction is critical for the obese patient (Blackburn, Am. J. Clin. Nujtr. 69:347-349 (1999), Galuska et al, JAMA 282:1576 (1999)). Moreover, high body weight alone puts an increased strain on the support and mobility apparatus, which can lead to chronic pain and diseases such as arthritis or osteoarthritis. Thus, obesity is a serious health problem for society.


There is good evidence that pharmacotherapy can enhance weight loss when combined with interventions aimed at changing life style (National Heart, Lung and Blood Institute, Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report, NIH Publication No. 98-4083, September 1998). Yet, the available pharmacological therapies to facilitate weight loss fail to provide adequate benefit to many obese patients because of side effects, contraindications or lack of positive response (National Heart, Lung and Blood Institute, Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report, NIH Publication No. 98-4083, September 1998). Hence, there is impetus for developing new and alternative treatments for management of obesity.


Apart from physical activity and a change in nutrition, there is currently no convincing treatment option for effectively reducing body weight. However, as obesity is a major risk factor in the development of serious and even life-threatening diseases, it is all the more important to have access to pharmaceutical active substances for the prevention and/or treatment of obesity.







DESCRIPTION OF THE INVENTION

The compound 1-[2-(4-(3-trifluoromethyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one (Flibanserin) is disclosed in form of its hydrochloride in European Patent Application EP-A-526434 and has the following chemical structure:




embedded image


Flibanserin shows affinity for the 5-HT1A receptor and the 5-HT2-receptor family. It is therefore a promising therapeutic agent for the treatment of a variety of diseases, for instance depression, schizophrenia and anxiety.


Surprisingly it has been found that Flibanserin, optionally in form of the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof proved to be a weight-loss agent and therefore is useful to treat obesity and related diseases.


As used herein, the term “obesity” means an excess of adipose tissue in the body. In this connection, obesity is fundamentally to be seen as the increased level of fatness which leads to a health risk. There is no sharp distinction between normal individuals, overweight individuals and those suffering from obesity, but the health risk accompanying obesity is presumed to rise continuously as the level of fatness increases. For simplicity's sake, in the present invention, individuals with a Body Mass Index (BMI), which is defined as the body weight measured in kilograms divided by the height (in meters) squared, above a value of 25 and more particularly above 30, are preferably regarded as suffering from obesity.


One object of the present invention is directed to the use of Flibanserin, optionally in form of the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the preparation of a medicament for the treatment and/or prevention of obesity.


The indication obesity includes in particular exogenic obesity, hyperinsulinaemic obesity, hyperplasmic obesity, hyperphyseal adiposity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, infantile obesity, upper body obesity, alimentary obesity, hypogonadal obesity and central obesity.


Therefore, the present invention is directed also to the use of Flibanserin, optionally in form of the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the preparation of a medicament for the treatment and/or prevention of exogenic obesity, hyperinsulinaemic obesity, hyperplasmic obesity, hyperphyseal adiposity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, infantile obesity, upper body obesity, alimentary obesity, hypogonadal obesity and central obesity.


In another embodiment, this invention relates to the use of Flibanserin, optionally in form of the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the preparation of a medicament for promoting, increasing or facilitating weight loss.


Furthermore, this invention relates to the use of Flibanserin, optionally in form of the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the preparation of a medicament for prevention of body weight gain.


In another embodiment, this invention relates to the use of Flibanserin, optionally in form of the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the preparation of a medicament for inhibiting or reducing appetite.


In another embodiment, this invention relates to the use of Flibanserin, optionally in form of the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, for the preparation of a medicament for the treatment and/or prevention of diseases and/or disorders associated with obesity, such as the metabolic syndrome (syndromeX), hypertension, osteoarthritis, diabetes, especially type II diabetes, complications of diabetes including diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, insulin resistance, pathological glucose tolerance, encephalorrhagia, heart diseases, cardiac insufficiency, arteriosclerosis, arthritis, gonitis, stroke and dyslipidaemia, preferably metabolic syndrome, diabetes and dyslipidaemia, comprising the administration of a therapeutically effective amount of Flibanserin, optionally in form of the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof.


Another embodiment of the present invention relates to a method of treating and/or preventing the above mentioned diseases and/or disorders comprising the administration of a therapeutically effective amount of Flibanserin, optionally in form of the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof.


For the treatment of the aforementioned diseases, Flibanserin, optionally in form of the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof may also be co-administered with a second active substance selected from the group consisting of

    • active substances for the treatment of diabetes,
    • active substances for the treatment of diabetic complications,
    • active substances for the treatment of obesity,
    • active substances for the treatment of high blood pressure,
    • active substances for the treatment of hyperlipidaemia, including arteriosclerosis,
    • active substances for the treatment of dyslipidaemia, including arteriosclerosis,
    • active substances for the treatment of arthritis.


Examples of active substances for the treatment of diabetes are insulin sensitisers, insulin secretion accelerators, biguanides, insulins, α-glucosidase inhibitors, β3 adrenoreceptor agonists.


Insulin sensitisers include glitazones, particularly pioglitazone and its salts (preferably hydrochloride), troglitazone, rosiglitazone and its salts (preferably maleate), JTT-501, GI-262570, MCC-555, YM-440, DRF-2593, BM-13-1258, KRP-297, R-119702 and GW-1929.


Insulin secretion accelerators include sulphonylureas, such as for example tolbutamide, chloropropamide, tolazamide, acetohexamide, glyclopyramide and its ammonium salts, glibenclamide, gliclazide, glimepiride. Further examples of insulin secretion accelerators are repaglinide, nateglinide, mitiglinide (KAD-1229) and JTT-608.


Biguanides include metformin, buformin and phenformin.


Insulins include those obtained from animals, particularly cattle or pigs, semisynthetic human insulins which are synthesised enzymatically from insulin obtained from animals, human insulin obtained by genetic engineering, e.g. from Escherichi coli or yeasts. Moreover, the term insulin also includes insulin-zinc (containing 0.45 to 0.9 percent by weight of zinc) and protamine-insulin-zinc obtainable from zinc chloride, protamine sulphate and insulin. Insulin may also be obtained from insulin fragments or derivatives (for example INS-1, etc.).


Insulin may also include different kinds, e.g. with regard to the onset time and duration of effect (“ultra immediate action type”, “immediate action type”, “two phase type”, “intermediate type”, “prolonged action type”, etc.), which are selected depending on the pathological condition of the patient.


α-Glucosidase inhibitors include acarbose, voglibose, miglitol, emiglitate.


β3 Adreno receptor agonists include AJ-9677, BMS-196085, SB-226552, AZ40140.


Active substances for the treatment of diabetes other than those mentioned above include ergoset, pramlintide, leptin, BAY-27-9955 as well as glycogen phosphorylase inhibitors, sorbitol dehydrogenase inhibitors, protein tyrosine phosphatase 1B inhibitors, dipeptidyl protease inhibitors, glipazide, glyburide.


Active substances for the treatment of diabetic complications include for example aldose reductase inhibitors, glycation inhibitors and protein kinase C inhibitors, DPPIV blockers, GLP-1 or GLP-2 analogues and SGLT-2 inhibitors.


Aldose reductase inhibitors are for example tolrestat, epalrestat, imirestat, zenarestat, SNK-860, zopolrestat, ARI-50i, AS-3201.


An example of a glycation inhibitor is pimagedine.


Protein Kinase C inhibitors are for example NGF, LY-333531.


DPPIV blockers are for example LAF237 (Novartis), MK431 (Merck) as well as 815541, 823093 and 825964 (all GlaxoSmithkline).


GLP-1 analogues are for example Liraglutide (NN2211) (NovoNordisk), CJC1131 (Conjuchem), Exenatide (Amylin).


SGLT-2 inhibitors are for example AVE-2268 (Aventis) and T-1095 (Tanabe, Johnson&Johnson).


Active substances other than those mentioned above for the treatment of diabetic complications include alprostadil, thiapride hydrochloride, cilostazol, mexiletine hydrochloride, ethyl eicosapentate, memantine, pimagedine (ALT-711).


Active substances for the treatment of obesity, other than Flibanserin, include lipase inhibitors and anorectics.


A preferred example of a lipase inhibitor is orlistat.


Examples of preferred anorectics are phenetermine, mazindol, fluoxetine, sibutramine, baiamine, (S)-sibutramine, SR-141716, NGD-95-1.


Active substances other than those mentioned above for the treatment of obesity include lipstatin, Rimonabant and topiramate


Moreover for the purposes of this application the active substance group of anti-obesity active substances also includes the anorectics, of which the β3 agonists, thyromimetic active substances and NPY antagonists should be emphasised. The range of substances which may be considered as preferred anti-obesity or anorectic active substances is indicated by the following additional list, by way of example: phenylpropanolamine, ephedrine, pseudoephedrine, phenetermine, a cholecystokinin-A (hereinafter referred to as CCK-A) agonist, a monoamine reuptake inhibitor (such as for example sibutramine), a sympathomimetic active substance, a serotonergic active substance (such as for example dexfenfluramine, fenfluramine, a 5-HT2C agonist such as BVT.933 or APD356), a dopamine antagonist (such as for example bromocriptine or pramipexol), a melanocyte-stimulating hormone receptor agonist or mimetic, an analogue of melanocyte-stimulating hormone, a cannabinoid receptor antagonist (Rimonabant, ACOMPLIA™), an MCH antagonist, the OB protein (hereinafter referred to as leptin), a leptin analogue, a fatty acid synthase (FAS) antagonist, a leptin receptor agonist, a galanine antagonist, a GI lipase inhibitor or reducer (such as for example orlistat). Other anorectics include bombesin agonists, dehydroepiandrosterone or its analogues, glucocorticoid receptor agonists and antagonists, orexin receptor antagonists, urocortin binding protein antagonists, agonists of the Glucagon-like Peptide-1 receptor, such as for example exendin, AC 2993, CJC-1131, ZP10 or GRT0203Y, DPPIV inhibitors and ciliary neurotrophic factors, such as for example axokines. In this context mention should also be made of the forms of therapy which produce weight loss by increasing the fatty acid oxidation in the peripheral tissue, such as for example inhibitors of acetyl-CoA carboxylase.


Active substances for the treatment of high blood pressure include inhibitors of angiotensin converting enzyme, calcium antagonists, potassium channel openers and angiotensin II antagonists.


Inhibitors of angiotensin converting enzyme include captopril, enalapril, alacepril, delapril (hydrochloride), lisinopril, imidapril, benazepril, cilazapril, temocapril, trandolapril, manidipine (hydrochloride).


Examples of calcium antagonists are nifedipine, amlodipine, efonidipine, nicardipine.


Potassium channel openers include levcromakalim, L-27152, AL0671, NIP-121.


Angiotensin II antagonists include telmisartan, losartan, candesartan cilexetil, valsartan, irbesartan, CS-866, E4177.


Active substances for the treatment of hyperlipidaemia, including arteriosclerosis, include HMG-CoA reductase inhibitors, fibrate compounds.


HMG-CoA reductase inhibitors include pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, lipantil, cerivastatin, itavastatin, ZD-4522 and their salts.


Fibrate compounds include bezafibrate, clinofibrate, clofibrate and simfibrate.


Active substances for the treatment of dyslipidaemia, including arteriosclerosis, include e.g. medicaments which raise the HDL level, such as e.g. nicotinic acid and derivatives and preparations thereof, such as e.g. niaspan, as well as agonists of the nicotinic acid receptor.


Active substances for the treatment of arthritis include NSAIDs (non-steroidal antiinflammatory drugs), particularly COX2 inhibitors, such as for example meloxicam or ibuprofen.


Accordingly, the invention also relates to combining separate pharmaceutical compositions in kit form which may be co-administered separately. Therefore, in a further embodiment the present invention provides a kit comprising a) a first pharmaceutical composition comprising an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of diabetes, active substances for the treatment of diabetic complications, active substances for the treatment of obesity, active substances for the treatment of high blood pressure, active substances for the treatment of hyperlipidaemia, including arteriosclerosis active substances for the treatment of dyslipidaemia, including arteriosclerosis, active substances for the treatment of arthritis, b) a second pharmaceutical composition comprising Flibanserin, optionally in form of the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof for the treatment of the above mentioned diseases; and a container for both compositions.


In a preferred embodiment the present invention provides a kit comprising a) a first pharmaceutical composition comprising one or more, preferably one active substance for the treatment of obesity, preferrably orlistat, phenetermine, sibutramine or topiramate; b) a second pharmaceutical composition comprising Flibanserin, optionally in form of the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof for the treatment of the above mentioned diseases; and a container for both compositions


The term “co-administration”, within the present invention means that both active ingredients mentioned above can be taken from the kit and combined for administration together as a composition or as part of the same, unitary dosage form, such as an parenterally or orally administered solution. “Co-administration” also includes administering the components separately (e.g. as tablets or capsules), but as part of the same therapeutic treatment program or regimen. Both components need not be administered at essentially the same time, although they can be if so desired. Thus “co-administration” includes, for example administering all active ingredients as separate dosages or dosage forms and at essentially the same time. The term also includes separate administration at different times, in any order, and if preferred by different routes of administration. An example of a kit is the so-called blister pack well known in the packaging industry particularly for packaging pharmaceutical dosage forms.


Instead of a kit, Flibanserin and the second active substance according to the invention can be combined in one dosage form. Therefore, the present invention also relates to compositions comprising Flibanserin optionally in form of the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof and a second active substance active being not flibanserin, selected from the group consisting of active substances for the treatment of diabetes, active substances for the treatment of diabetic complications, active substances for the treatment of obesity, active substances for the treatment of high blood pressure, active substances for the treatment of hyperlipidaemia, including arteriosclerosis active substances for the treatment of dyslipidaemia, including arteriosclerosis, active substances for the treatment of arthritis in one dosage form.


Preferably, the present invention also relates to compositions comprising a) one or more, preferably one active substance for the treatment of obesity preferrably orlistat, phenetermine, sibutramine or topiramate and b) Flibanserin, optionally in form of the free base, the pharmacologically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof.


Above mentioned kits and compositions can be used for the treatment and/or prevention of obesity like exogenic obesity, hyperinsulinaemic obesity, hyperplasmic obesity, hyperphyseal adiposity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, infantile obesity, upper body obesity, alimentary obesity, hypogonadal obesity and central obesity as well as for promoting, increasing or facilitating of weight loss, for the prevention of body weight gain, and for inhibiting or reducing appetite.


Furthermore the above mentioned kits and compositions can be used for the treatment and/or prevention of diseases and/or disorders associated with obesity, such as the metabolic syndrome (syndromeX), hypertension, osteoarthritis, diabetes, especially type II diabetes, complications of diabetes including diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, insulin resistance, pathological glucose tolerance, encephalorrhagia, heart diseases, cardiac insufficiency, arteriosclerosis, arthritis, gonitis, stroke and dyslipidaemia, preferably metabolic syndrome, diabetes and dyslipidaemia.


As already mentioned above, Flibanserin may be used in form of the free base, optionally in form of its pharmaceutically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof. Suitable acid addition salts include for example those of the acids selected from, succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid and citric acid. Mixtures of the abovementioned acid addition salts may also be used. From the aforementioned acid addition salts the hydrochloride and the hydrobromide, particularly the hydrochloride, are preferred. If Flibanserin is used in form of the free base, it is preferably used in form of Flibanserin polymorph A as disclosed in WO 03/014079.


The active substances which are suitable to be combined with Flibanserin within the teaching of the instant invention and which are mentioned hereinbefore may also be capable of forming acid addition salts with pharmaceutically acceptable acids. Representative salts include the following: Acetate, Benzenesulfonate, Benzoate, Bicarbonate, Bisulfate, Bitartrate, Borate, Bromide, Camsylate, Carbonate, Chloride, Clavulanate, Citrate, Dihydrochloride, Edetate, Edisylate, Estolate, Esylate, Fumarate, Gluceptate, Gluconate, Glutamate, Glycollylarsanilate, Hexylresorcinate, Hydrabamine, Hydrobromide, Hydrochloride, Hydroxynaphthoate, Iodide, Isothionate, Lactate, Lactobionate, Laurate, Malate, Maleate, Mandelate, Mesylate, Methylbromide, Methylnitrate, Methylsulfate, Mucate, Napsylate, Nitrate, N-methylglucamine ammonium salt, Oleate, Oxalate, Pamoate (Embonate), Palmitate, Pantothenate, Phosphate/diphosphate, Polygalacturonate, Salicylate, Stearate, Sulfate, Subacetate, Succinate, Tannate, Tartrate, Teoclate, Tosylate, Triethiodide and Valerate.


Furthermore, where the other anti-obesity compounds carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.


The active substances which are suitable to be combined with Flibanserin may have chiral centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. Therefore, where a compound is chiral, the separate enantiomers, substantially free of the other, are included within the scope of the invention. Further included are all mixtures of the two enantiomers. Also included within the scope of the invention are polymorphs and hydrates of the compounds of the instant invention.


The present invention includes within its scope prodrugs of Flibanserin and of the active substances which are suitable to be combined with Flibanserin. In general, such prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound.


Flibanserin, optionally used in form of its pharmaceutically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof, or in form of Flibanserin polymorph A, as well as the other anti-obesity compounds may be incorporated into the conventional pharmaceutical preparation in solid, liquid or spray form. The compositions may, for example, be presented in a form suitable for oral, rectal, parenteral administration or for nasal inhalation: preferred forms includes for example, capsules, tablets, coated tablets, ampoules, suppositories and nasal spray.


The active ingredients may be incorporated in excipients or carriers conventionally used in pharmaceutical compositions such as, for example, talc, arabic gum, lactose, gelatine, magnesium stearate, corn starch, acqueous or non acqueous vehicles, polyvynil pyrrolidone, semisynthetic glicerides of fatty acids, benzalconium chloride, sodium phosphate, EDTA, polysorbate 80. The compositions are advantageously formulated in dosage units, each dosage unit being adapted to supply a single dose of the active ingredient.


Within the instant invention flibanserin is preferably administered in such an amount that per single dosage between 0.01 to 400 mg of flibanserin are applied. Preferred are ranges of between 1.0 to 300 mg, particular preferred 2.0 to 200 mg of flibanserin. Suitable dosage forms may contain for instance 5, 10, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 mg of flibanserin. The doses range applicable per day is between 0.1 to 400, preferably between 1.0 to 300, more preferably between 2 to 200 mg. The aforementioned values are based on flibanserin in form of the free base. If flibanserin is applied in form of one of its acid addition salts, the corresponding values are readily calculable from the aforementioned values. Advantageously, flibanserin may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.


The dosage of the active ingredients suitable for coadministration with flibanserin in the compositions of this invention may be varied. However, it is necessary that the amount of the active ingredients be such that a suitable dosage form is obtained. The selected dosage and the dosage form depend upon the desired therapeutic effect, on the route of administration and on the duration of the treatment. Dosage ranges in the combination are approximately one tenth to one times the clinically effective ranges required to induce the desired therapeutic effect, respectively when the compounds are used singly.


In case of the preferred compound orlistat particularly preferred doses per day are in the range of about 100 to 400 mg. In case of the preferred compound sibutramine particularly preferred doses per day are in the range of about 5 to 15 mg. In case of the preferred compound phenetermine particularly preferred doses per day are in the range of about 30 to 90 mg. Suitable dosage forms may contain for instance 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 mg of the above mentioned compounds. Advantageously, the compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.


Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.


Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number or layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.


Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. of a flavouring such as vanilline or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.


Solutions for injection are prepared in the usual way, e.g. of with the addition of preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, and transferred into injection vials or ampoules.


Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.


Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.


The Examples which follow illustrate the present invention without restricting its scope:


Examples of Pharmaceutical Formulations

















A)
Tablets
per tablet



















Flibanserin hydrochloride
100 mg



lactose
240 mg



corn starch
340 mg



polyvinylpyrrolidone
 45 mg



magnesium stearate
 15 mg




740 mg










The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.

















B)
Tablets
per tablet



















Flibanserin hydrochloride
80 mg



corn starch
190 mg 



lactose
55 mg



microcrystalline cellulose
35 mg



polyvinylpyrrolidone
15 mg



sodium-carboxymethyl starch
23 mg



magnesium stearate
 2 mg




400 mg 










The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodium-carboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.

















C)
Coated tablets
per coated tablet










Flibanserin hydrochloride
 5 mg




corn starch
41.5 mg  




lactose
30 mg




polyvinylpyrrolidone
 3 mg




magnesium stearate
0.5 mg 





80 mg










The active substance, corn starch, lactose and polyvinylpyrrolidone are thoroughly mixed and moistened with water. The moist mass is pushed through a screen with a 1 mm mesh size, dried at about 45° C. and the granules are then passed through the same screen. After the magnesium stearate has been mixed in, convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine. The tablet cores thus produced are coated in known manner with a covering consisting essentially of sugar and talc. The finished coated tablets are polished with wax.

















D)
Capsules
per capsule










Flibanserin hydrochloride
150 mg




Corn starch
268.5 mg  




Magnesium stearate
 1.5 mg





420 mg










The substance and corn starch are mixed and moistened with water. The moist mass is screened and dried. The dry granules are screened and mixed with magnesium stearate. The finished mixture is packed into size 1 hard gelatine capsules.
















E)
Ampoule solution





















Flibanserin hydrochloride
50 mg




sodium chloride
50 mg




water for inj.
 5 ml










The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion.
















F)
Suppositories





















Flibanserin hydrochloride
 50 mg




solid fat
1650 mg





1700 mg










The hard fat is melted. At 40° C. the ground active substance is homogeneously dispersed. It is cooled to 38° C. and poured into slightly chilled suppository moulds.


In a particular preferred embodiment of the instant invention, Flibanserin is administered in form of specific film coated tablets. Examples of these preferred formulations are listed below. The film coated tablets listed below can be manufactured according to procedures known in the art (see hereto WO 03/097058).












G) Film coated tablet










Constituents
mg/tablet











Core










Flibanserin
25.000



Lactose monohydrate
71.720



Microcrystalline cellulose
23.905



HPMC (Methocel E5)
1.250



Carboxymethylcellulose sodium
2.500



Magnesium stearate
0.625







Coating










HPMC (Methocel E5)
1.440



Polyethylene Glycol 6000
0.420



Titanium dioxide
0.600



Talc
0.514



Iron oxide red
0.026



Total Film coated tablet
128.000




















H) Film coated tablet










Constituents
mg/tablet











Core










Flibanserin
50.000



Lactose monohydrate
143.440



Microcrystalline cellulose
47.810



HPMC (e.g. Pharmacoat 606)
2.500



Carboxymethylcellulose sodium
5.000



Magnesium stearate
1.250







Coating










HPMC (e.g. Pharmacoat 606)
2.400



Polyethylene Glycol 6000
0.700



Titanium dioxide
1.000



Talc
0.857



Iron oxide red
0.043



Total Film coated tablet
255.000




















I) Film coated tablet










Constituents
mg/tablet











Core










Flibanserin
100.000



Lactose monohydrate
171.080



Microcrystalline cellulose
57.020



HPMC (e.g. Methocel E5)
3.400



Carboxymethylcellulose sodium
6.800



Magnesium stearate
1.700







Coating










HPMC (e.g. Methocel E5)
3.360



Polyethylene Glycol 6000
0.980



Titanium dioxide
1.400



Talc
1.200



Iron oxide red
0.060



Total Film coated tablet
347.000




















J) Film coated tablet










Constituents
mg/tablet











Core










Flibanserin
2.000



Dibasic Calciumphosphate, anhydrous
61.010



Microcrystalline cellulose
61.010



HPMC (Methocel E5)
1.950



Carboxymethylcellulose sodium
2.600



Colloidal silicon dioxide
0.650



Magnesium stearate
0.780







Coating










HPMC (Methocel E5)
1.440



Polyethylene Glycol 6000
0.420



Titanium dioxide
0.600



Talc
0.514



Iron oxide red
0.026



Total Film coated tablet
133.000




















K) Film coated tablet










Constituents
mg/tablet











Core










Flibanserin
100.000



Dibasic Calciumphosphate, anhydrous
69.750



Microcrystalline cellulose
69.750



HPMC (e.g. Methocel E5)
2.750



Carboxymethylcellulose sodium
5.000



Colloidal silicon dioxide
1.250



Magnesium stearate
1.500







Coating










HPMC (e.g. Methocel E5)
2.400



Polyethylene Glycol 6000
0.700



Titanium dioxide
1.043



Talc
0.857



Total Film coated tablet
255.000




















L) Film coated tablet










Constituents
mg/tablet











Core










Flibanserin
20.000



Lactose monohydrate
130.000



Microcrystalline cellulose
43.100



Hydroxypropyl Cellulose (e.g. Klucel LF)
1.900



Sodium Starch Glycolate
4.000



Magnesium stearate
1.000







Coating










HPMC (e.g. Methocel E5)
2.400



Polyethylene Glycol 6000
0.700



Titanium dioxide
1.043



Talc
0.857



Total Film coated tablet
205.000




















M)










Constituents
mg/tablet











Core










Flibanserin (free base)
50.000



Orlistat
120.000



Anhydrous dibasic calcium phosphate
100.000



Microcrystalline cellulose
203.090



HPMC (Methocel E5)
6.615



Croscarmellose sodium
8.820



Magnesium stearate
2.250







Coating










HPMC (Methocel E5)
4.320



Polyethylene Glycol 6000
1.260



Titanium dioxide
1.800



Talc
1.542



Iron oxide red
0.078



Total Film coated tablet
499.775
























Constituents
mg/tablet
















N)


Core:










Flibanserin (free base)
50.000



Sibutramine
10.000



Lactose monohydrate
133.750



Microcrystalline cellulose
40.000



Hydroxypropylcellulose
2.500



Corn starch
12.500



Magnesium stearate
1.250







Coating










HPMC (e.g. Pharmacoat 606)
2.400



Polyethylene Glycol 6000
0.700



Titanium dioxide
1.000



Talc
0.857



Iron oxide yellow
0.043



Total Film coated tablet
255.000




















O)










Constituents
mg/tablet











Core










Flibanserin (free base)
50.000



Phenetermine
30.000



Lactose monohydrate
143.490



Microcrystalline cellulose
47.810



HPMC (e.g. Pharmacoat 606)
2.500



Carboxymethylcellulose sodium
5.000



Mannitol
60.000



Corn starch
36.500



Povidone
1.000



Colloidal silicon dioxide
1.000



Magnesium stearate
1.700







Coating










HPMC (e.g. Methocel E5)
3.360



Polyethylene Glycol 6000
0.980



Titanium dioxide
1.400



Talc
1.200



Iron oxide red
0.060



Total Film coated bilayer tablet
386.000











Pharmacological Experiments:


To test the efficacy of Flibanserin in the treatment of obesity groups of the rats per sex per group (gang-housed) received Flibnanserin at dosages of 0 (control), 100, 200, and 600 mg/kg/day via dietary admixture. The test compound was mixed with the food to obtain a 3% premix. This premix was prepared in week −1 and drug week 7 and was used to prepare the substance/food mixtures for all individual groups. The substance/food concentration was calculated using the mean daily food intake from the study week before. The substance/food mixture was made weekly for every dose group and stored under darkness in the animal room. The concentration, homogeneity and stability of the test substance in the food was checked during study week 2 with reanalysis one and four weeks later. One further check of concentration and homogeneity was performed in week 13. The body weight of each animal was determined and recorded once a week including the pretest acclimation period, in the morning on the same day of the week.


The following tables presents the results of the above described experiments as absolute body weights at start of treatment (week −1) as well as in drug week 6 and 13, including percentage change compared to controls. (in parentheses).









TABLE 1







Table. Mean absolute body weights of males# in grams and


percent change to controls








Drug
Dosage BIMT 17 BS (mg/kg/day)











week
0 (Controls)
100
200
600














−1
191.3
188.1 (−1.7)
189.3 (−1.0)
186.8 (−2.4)


6
368.2
340.9 (−7.4)↓
340.4 (−7.5)↓
284.8 (−22.7)↓


13
440.4
397.4 (−9.8)↓
400.9 (−9.0)↓
333.2 (−24.3)↓





↓significantly decreased compared to controls (p < 0.05; t-test, pooled variance)



#n = 10/group














TABLE 2







Table. Mean absolute body weights of females# in grams and


percent change to controls








Drug
Dosage BIMT 17 BS (mg/kg/day)











week
0 (Controls)
100
200
600














−1
141.2
141.3 (+0.1)
142.2 (+0.7)
140.7 (−0.4)


6
229.1
213.6 (−6.8)↓
209.7 (−8.5)↓
196.0 (−14.4)↓


13
261.5
234.5 (−10.3)↓
234.9 (−10.2)↓
225.8 (−13.7)↓





↓significantly decreased compared to controls (p < 0.05; t-test, pooled variance)



#n = 10/group







From Tables 1 and 2 it can be taken that the body weight gain of males and females were significantly decreased in almost all drug weeks. At study end the difference compared to controls was 10%, 9% and 24% in males and 10%, 10% and 14% in females at 100, 200 and 600 mg/kg/day, respectively.


This pharmacological data provide evidence for the efficacy of Flibanserin in the treatment of obesity and can be used for the preparation of a medicament for promoting, increasing or facilitating weight loss and for inhibiting or prevention of body weight gain.

Claims
  • 1. A method of treating obesity comprising administering to an individual in need thereof a therapeutically effective amount of flibanserin, or a pharmacologically acceptable acid addition salt thereof.
  • 2. The method according to claim 1, wherein obesity comprises exogenic obesity, hyperinsulinaemic obesity, hyperplasmic obesity, hyperphyseal adiposity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, infantile obesity, upper body obesity, alimentary obesity, hypogonadal obesity, or central obesity.
  • 3. The method of claim 1, further comprising administering a second active ingredient comprising orlistat, phenetermine, sibutramine, or topiramate, or a pharmaceutical acceptable salt thereof.
  • 4. The method of claim 1, further comprising administering a second active ingredient comprising ergoset, pramlintinide, leptin, BAY-27-9955, glipazide, glyburide, alprostadil, thipride hydrochloride, cilostazol, mexiletine hydrochloride, ethyl eicosapentate, memantine, or pimagedine, or a pharmaceutical acceptable salt thereof.
  • 5. The method of claim 1, further comprising administering a second active ingredient comprising pioglitazone or a pharmaceutical acceptable salt thereof, troglitazone, rosiglitazone or a pharmaceutical acceptable salt thereof, JTT-501, GI-262570, MCC-555, YM-440, DRF-2593, BM-13-1258, KRP-297, R-119702, GW-1929, tolbutamide, chloropropamide, tolazamide, acetohexamide, glyclopyramide, an ammonium salt of glyclopyramide, glibenclamide, gliclazide, glimepiride, repaglinide, nateglinide, mitiglinide, JTT-608, metformin, bovine insulin, porcine insulin, semisynthetic human insulin, genetically-engineered human insulin, acarbose, voglibose, miglitol, emiglitate, AJ-9677, BMS-196085, SB-226552, AZ40140, tolrestat, epalrestat, imirestat, zenarestat, SNK-860, zopolrestat, ARI-50i, AS-3201, NGF, LY-333531, LAF237, MK431, 815541, 823093, 825964, liraglutide, exenatide, AVE-2268, T-1095, mazindol, baiamine, NGD-95-1, lipstatin, rimonabant, phenylpropanolamine, ephedrine, pseudroephedrine, dexfenfluramine, fenfluramine, BVT.933, APD356, bromocriptine, pramipexol, dehydroepiandrosterone, exendin, AC 2993, CJC-1131, ZP10, GRT0203Y, captopril, enalapril, alacepril, delapril, lisinopril, imidapril, benazepril, cilazapril, temocapril, trandolapril, manidipine, nifedipine, amlodipine, efonidipine, nicardipine, levcromakalim, L-27152, AL0671, NIP-121, telmisartan, losartan, candesartan cilexetil, valsartan, irbesartan, CS-866, E4177, pravastatin or a pharmaceutical acceptable salt thereof, simvastatin or a pharmaceutical acceptable salt thereof, lovastatin or a pharmaceutical acceptable salt thereof, atorvastatin or a pharmaceutical acceptable salt thereof, fluvastatin or a pharmaceutical acceptable salt thereof, lipantil or a pharmaceutical acceptable salt thereof, cerivastatin or a pharmaceutical acceptable salt thereof, itavastatin or a pharmaceutical acceptable salt thereof, ZD-4522 or a pharmaceutical acceptable salt thereof, bezafibrate, clinofibrate, clofibrate, simfibrate, meloxicam, ibuprofen, or mixtures thereof.
Priority Claims (1)
Number Date Country Kind
05016867 Aug 2005 EP regional
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/EP2006/064825 7/31/2006 WO 00 3/21/2008
Publishing Document Publishing Date Country Kind
WO2007/014929 2/8/2007 WO A
US Referenced Citations (101)
Number Name Date Kind
3096248 Rudzki Jul 1963 A
3406178 Crocker et al. Oct 1968 A
3472854 Archer Oct 1969 A
4200641 Vandenberk et al. Apr 1980 A
4367217 Gruber et al. Jan 1983 A
4737500 Sorg Apr 1988 A
4792452 Howard et al. Dec 1988 A
4797399 Ueda et al. Jan 1989 A
4859692 Bernstein et al. Aug 1989 A
4886803 Sueda et al. Dec 1989 A
4940793 Botrè et al. Jul 1990 A
4954503 Strupczewski et al. Sep 1990 A
4968508 Oren et al. Nov 1990 A
5002948 Perregaard et al. Mar 1991 A
5036088 Kitaura et al. Jul 1991 A
5225417 Dappen et al. Jul 1993 A
5405642 Gilis et al. Apr 1995 A
5407686 Patel et al. Apr 1995 A
5434156 Björk et al. Jul 1995 A
5492907 Pickar et al. Feb 1996 A
5552412 Cameron et al. Sep 1996 A
5576318 Bietti et al. Nov 1996 A
5591743 Patoiseau et al. Jan 1997 A
5854290 Arnsten et al. Dec 1998 A
5883094 Fliri et al. Mar 1999 A
5916916 Hauser et al. Jun 1999 A
5929054 Baker et al. Jul 1999 A
5977106 Patoiseau et al. Nov 1999 A
6068846 Cho et al. May 2000 A
6083947 Granger et al. Jul 2000 A
6165513 Dansereau et al. Dec 2000 A
6187340 Fukuta et al. Feb 2001 B1
6281218 Cereda et al. Aug 2001 B1
6284757 Sanner Sep 2001 B1
6346548 Miller et al. Feb 2002 B1
6426087 Saslawski et al. Jul 2002 B1
6482841 Letelier et al. Nov 2002 B1
6521623 Cereda et al. Feb 2003 B1
6586435 Cereda et al. Jul 2003 B2
6627646 Bakale et al. Sep 2003 B2
6680071 Johnson et al. Jan 2004 B1
7151103 Borsini et al. Dec 2006 B2
7183410 Bombarda et al. Feb 2007 B2
7420057 Bombarda et al. Sep 2008 B2
20020001397 Ishikawa et al. Jan 2002 A1
20020010216 Rogosky et al. Jan 2002 A1
20020103208 Cereda et al. Aug 2002 A1
20020151543 Barberish et al. Oct 2002 A1
20030027823 Cereda et al. Feb 2003 A1
20030060475 Borsini Mar 2003 A1
20030083228 Carpino et al. May 2003 A1
20030104980 Borsini et al. Jun 2003 A1
20030119850 Bombarda et al. Jun 2003 A1
20040023948 Green et al. Feb 2004 A1
20040048877 Friedl et al. Mar 2004 A1
20040116532 Heacock et al. Jun 2004 A1
20040132697 Thurlow et al. Jul 2004 A1
20040147581 Taylor et al. Jul 2004 A1
20040180904 Beck Sep 2004 A1
20040193452 Berman Sep 2004 A1
20040235861 Borsini Nov 2004 A1
20040258749 Guldner et al. Dec 2004 A1
20050004105 Leahy et al. Jan 2005 A1
20050037983 Dinan et al. Feb 2005 A1
20050065158 Naylor et al. Mar 2005 A1
20050095293 Brauns et al. May 2005 A1
20050159430 Bombarda et al. Jul 2005 A1
20050239798 Pyke Oct 2005 A1
20050245539 Mendla et al. Nov 2005 A1
20060014757 Pyke Jan 2006 A1
20060025420 Brauns et al. Feb 2006 A1
20060052391 Dolsten Mar 2006 A1
20060160822 Borsini Jul 2006 A1
20060199805 Pyke et al. Sep 2006 A1
20060204486 Pyke et al. Sep 2006 A1
20060211685 Pyke et al. Sep 2006 A1
20060252773 Ceci et al. Nov 2006 A1
20060258640 Ceci et al. Nov 2006 A1
20060264511 Pyke Nov 2006 A1
20060264512 Pyke Nov 2006 A1
20070032654 Bombarda et al. Feb 2007 A1
20070032655 Bombarda et al. Feb 2007 A1
20070072872 Borsini et al. Mar 2007 A1
20070105869 Pollentier et al. May 2007 A1
20070123540 Ceci May 2007 A1
20070196473 Friedl et al. Aug 2007 A1
20070265276 Pollentier et al. Nov 2007 A1
20080038346 Eisenreich et al. Feb 2008 A1
20080038347 Eisenreich et al. Feb 2008 A1
20080069873 Pearnchob et al. Mar 2008 A1
20080103155 Mendla et al. May 2008 A1
20080119482 Dolsten May 2008 A1
20080242678 Ceci et al. Oct 2008 A1
20080242679 Ceci Oct 2008 A1
20090023712 Ferger et al. Jan 2009 A1
20090054458 Bombarda et al. Feb 2009 A1
20090176698 Baiker et al. Jul 2009 A1
20090239881 Becker Sep 2009 A1
20090247546 Ceci et al. Oct 2009 A1
20090312242 Castro et al. Dec 2009 A1
20090318469 Pyke et al. Dec 2009 A1
Foreign Referenced Citations (92)
Number Date Country
904945 Dec 1986 BE
2455628 Feb 2003 CA
1033-1999 May 1999 CL
2394-1999 Oct 1999 CL
1491-2001 Jun 2001 CL
2833-2001 Nov 2001 CL
418-2002 Mar 2002 CL
1706-2002 Jul 2002 CL
1878-2002 Aug 2002 CL
2389-2002 Oct 2002 CL
1751-2004 Jul 2004 CL
911-2005 Apr 2005 CL
1571670 Jan 2005 CN
1655789 Aug 2005 CN
3620643 Jan 1987 DE
10209982.0 Mar 2002 DE
10138273 Feb 2003 DE
0200322 Nov 1986 EP
0376607 Jul 1990 EP
0497985 Aug 1992 EP
0526434 Feb 1993 EP
0705832 Apr 1996 EP
0816356 Jan 1998 EP
0982030 Mar 2000 EP
1256343 Nov 2002 EP
1285658 Feb 2003 EP
1285658 Feb 2003 EP
1014985 May 2003 EP
1518858 Mar 2005 EP
1674102 Jun 2006 EP
2023594 Jan 1980 GB
19921340 Oct 1992 IE
159151 Feb 2003 IL
160389 Feb 2004 IL
8-143476 Jun 1996 JP
93014306 Mar 1995 RU
WO 9202215 Feb 1992 WO
9203167 Mar 1992 WO
9219606 Nov 1992 WO
9303016 Feb 1993 WO
9501965 Jan 1995 WO
WO 9519978 Jul 1995 WO
9534555 Dec 1995 WO
9605834 Feb 1996 WO
9616949 Jun 1996 WO
WO 9819668 May 1998 WO
9833784 Aug 1998 WO
9842344 Oct 1998 WO
9919302 Apr 1999 WO
WO 9959593 May 1999 WO
WO 9959584 Nov 1999 WO
0028993 May 2000 WO
WO 0024383 May 2000 WO
WO 0063193 Oct 2000 WO
0064441 Nov 2000 WO
WO 0067735 Nov 2000 WO
WO 0100224 Jan 2001 WO
0112170 Feb 2001 WO
0121593 Mar 2001 WO
WO 0200654 Jan 2002 WO
0224662 Mar 2002 WO
WO 0241894 May 2002 WO
WO 02072586 Sep 2002 WO
02079143 Oct 2002 WO
WO 03007949 Jan 2003 WO
03011396 Feb 2003 WO
03013539 Feb 2003 WO
03014079 Feb 2003 WO
03035072 May 2003 WO
WO 03074032 Sep 2003 WO
03097058 Nov 2003 WO
2004041259 May 2004 WO
2004045509 Jun 2004 WO
2004069339 Aug 2004 WO
2005007166 Jan 2005 WO
WO 2005007166 Jan 2005 WO
2005044238 May 2005 WO
2005087207 Sep 2005 WO
2005102343 Nov 2005 WO
2005102342 Nov 2005 WO
2006010574 Feb 2006 WO
2006019715 Feb 2006 WO
WO 2006024471 Mar 2006 WO
2006096435 Sep 2006 WO
WO 2006096434 Sep 2006 WO
2006125041 Nov 2006 WO
2007014929 Feb 2007 WO
WO 2007023325 Mar 2007 WO
2007048803 May 2007 WO
WO 2007090091 Aug 2007 WO
WO 2008006839 Jan 2008 WO
WO 2008022932 Feb 2008 WO
Related Publications (1)
Number Date Country
20080242678 A1 Oct 2008 US